Thrombus News and Research

RSS

A blood clot or thrombus, is the final product of the blood coagulation step in hemostasis. It is achieved via the aggregation of platelets that form a platelet plug, and the activation of the humoral coagulation system (i.e. clotting factors).

Robotic surgery reduces readmissions, benefits patients' overall recovery

A new study, published in JAMA, has found that robotic surgery reduces the chance of readmission by half (52 per cent), and revealed a "striking" four-fold (77 per cent) reduction in prevalence of blood clots (deep vein thrombus and pulmonary emboli) - a significant cause of health decline and morbidity - when compared to patients who had open surgery.

15 May 2022

Free SARS-CoV-2 spike protein fragments may trigger platelet activation and clot formation in COVID-19

In a recent study under review in the Nature Portfolio journal and currently available on the Research Square* preprint server, researchers investigated the presence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein (SP) in the thrombi (or blood clots).

5 May 2022

Role of complement factor H-related protein 5 in venous thromboembolism and COVID-19

A new study discussed the role of complement factor H-related protein 5 (CFHR5) in venous thromboembolism (VTE) patients and hospitalized COVID-19 patients.

25 Apr 2022

New insight about how blood clots are formed during wound healing

Research carried out by RCSI University of Medicine and Health Sciences has revealed new information about how blood clots are formed during wound healing.

11 Mar 2022

Studying coagulopathy in COVID-19

A new study published in the journal Diagnostics provided an overview of ROTEM with a particular focus on interpreting the symmetrical clot formation curve. Researchers also introduced new parameters that could aid in distinguishing between COVID-19 patients and outcomes.

28 Feb 2022

Scientists decipher molecular cause of cerebral venous thrombosis

Cerebral venous thrombosis is a rare, often severe disease that has been brought to public attention by the Covid 19 pandemic. A research group from Würzburg has now succeeded for the first time in deciphering a molecular cause of this disease.

11 Feb 2022

Clinical trial compares Amulet with Watchman FLX device for percutaneous left atrial appendage closure

SWISS-APERO is the first randomized clinical trial comparing Amulet with the new generation Watchman FLX device in terms of residual left atrial appendage (LAA) patency after percutaneous LAA closure (LAAC) as evaluated by 45-day cardiac computed tomography angiography (CCTA).

8 Nov 2021

Caspase-11 identified as regulator of inflammatory pathology in SARS-CoV-2 infections

New findings identify CASP4/11 as detrimental to inflammation and coagulopathy associated with SARS-CoV-2 infection.

28 Sep 2021

Changes in fibrin clot structure contributes to thrombosis risk in severe COVID-19

Researchers from Europe recently demonstrated altered levels of factor XII (FXII) and its activation products in 2 independent cohorts of critically ill patients with COVID-19 compared to patients suffering from severe acute respiratory distress syndrome caused by the influenza virus (acute respiratory distress syndrome (ARDS)-influenza).

21 Sep 2021

RedHill provides opaganib treatment under compassionate use exemption for Swiss COVID-19 patients

RedHill Biopharma Ltd., a specialty biopharmaceutical company, today announced that it has acted on a request to provide opaganib treatment on an outpatient basis under compassionate use exemption for several Swiss patients suffering from COVID-19 pneumonia.

22 Mar 2021

Study reveals novel approach to reduce the risk of thrombosis by using IgM antibodies

Thrombotic occlusion of blood vessels, which leads to myocardial infarctions, strokes and venous thromboembolisms, is the major cause of death in the western hemisphere.

9 Mar 2021

DSMB recommends continuation of Phase 2/3 study of opaganib for severe COVID-19

RedHill Biopharma Ltd., a specialty biopharmaceutical company, today announced that the independent Data Safety Monitoring Board (DSMB) for the global Phase 2/3 study of opaganib in patients with severe COVID-19, unanimously recommended to continue the study following a pre-scheduled futility review of unblinded efficacy data from the first 135 patients treated in the study and safety data from the first 175 patients.

30 Jan 2021

Scientists engineer potent trivalent inhibitors of thrombin

Thrombosis, the clogging of blood vessels, is a major cause of heart attacks and embolism. Scientists have now engineered the first inhibitors of thrombin, a protease promoting thrombosis, that is three-fold efficient.

29 Jan 2021

Inhibition of blood clotting factor reduces the formation of brain metastases in mice

Brain metastases can only develop if cancer cells first exit the fine blood vessels and enter into the brain tissue.

5 Jan 2021

RedHill Biopharma announces promising preliminary results from opaganib study

TEL AVIV, Israel and RALEIGH, NC, December 15, 2020, RedHill Biopharma Ltd., a specialty biopharmaceutical company, today announced promising preliminary results from a preclinical study with opaganib.

15 Dec 2020

Aprotinin inhibits SARS-CoV-2 entry and replication in cells cultures

Researchers at the University of Kent in the UK and the Hannover Medical School and Goethe University in Germany have observed that the protease inhibitor aprotinin can inhibit viral replication by preventing SARS-CoV-2 entry into host cells.

24 Nov 2020

Pathways contributing to hypercoagulability in severe SARS‐CoV‐2 patients

In a study by researchers explored the possible mechanisms of the clotting disorder, focusing on the role of hypoxia-related activation of coagulation factors; cytokine storm, activation of neutrophils, and the release of neutrophil extracellular traps.

11 Oct 2020

Researchers provide unique experiment for creating artificial tissue-engineered vascular graft

Researchers from St. Petersburg provided a unique experiment. They implanted a polymer scaffold as a vascular prosthesis into the rat abdominal aorta and monitored the process of its bioresobtion for 16 months. An artificial vessel was formed where the scaffold was located.

9 Oct 2020

Study identifies effective treatment for severe COVID-19 patients

As countries around the world race to develop a vaccine for SARS-CoV-2, the virus responsible for COVID-19, researchers are working to understand exactly how it causes the myriad of symptoms that seem to linger long after active viral infection.

31 Aug 2020

COVID-19 associated with serious blood clots in leg arteries

COVID-19 is associated with life-threatening blood clots in the arteries of the legs, according to a study published in Radiology.

16 Jul 2020